Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WSK-IM02 in platinum-resistant recurrent ovarian cancer
NCT07462468Phase 1Not yet recruiting
- Sponsor
- WestVac Biopharma
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Modality
- Lipid-based Nanoparticles, Vaccines & Immunotherapeutics
01
Overview
Phase 1, open-label trial of WSK-IM02 in ovarian cancer (2 arms), sponsored by WestVac Biopharma. Primary endpoints: Dose-Limiting Toxicity at 4 weeks, Maximum Tolerated Dose at 4 weeks and 1 more. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
WSK-IM02
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT07462468.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07462468.